Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $62 | $60 | $67 | $68 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $16 | $18 | $20 | $20 |
| Inventory | $10 | $8 | $7 | $10 |
| Other Curr. Assets | $4 | $4 | $4 | $1 |
| Total Curr. Assets | $92 | $90 | $99 | $99 |
| Property Plant & Equip (Net) | $3 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $2 | $2 | $2 | $2 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $20 | $19 | $18 | $18 |
| Total NC Assets | $25 | $22 | $21 | $22 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $117 | $113 | $120 | $121 |
| Liabilities | – | – | – | – |
| Payables | $8 | $5 | $7 | $8 |
| Short-Term Debt | $0 | $0 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $15 | $14 | $16 | $17 |
| Total Curr. Liab. | $23 | $19 | $24 | $25 |
| LT Debt | $3 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $4 | $4 | $4 | $3 |
| Total NC Liab. | $7 | $4 | $4 | $3 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $1 | $1 |
| Total Liabilities | $30 | $23 | $28 | $28 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$496 | -$492 | -$487 | -$480 |
| AOCI | -$1 | $1 | $2 | -$0 |
| Other Equity | $584 | $580 | $577 | $573 |
| Total Equity | $87 | $89 | $92 | $92 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $117 | $113 | $120 | $121 |
| Net Debt | -$59 | -$60 | -$66 | -$67 |